BackPreveCeutical Medical Overview

PreveCeutical Medical Intangible Assets

PreveCeutical Medical's intangible assets is $210K.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$211542.00
↑ 34.10% YoYΔ $53793.00 vs prior year quarter

Peer trimmed avg / median

Loading

PreveCeutical Medical Intangible Assets History

Loading

PreveCeutical Medical vs. peers: Intangible Assets Comparison

Loading

PreveCeutical Medical Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

PreveCeutical Medical (PREV.CN) FAQ

PreveCeutical Medical's intangible assets stands at $210K as of June 2026. That compares with $160K in the prior-year period — up 34.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

PreveCeutical Medical reported $210K in intangible assets versus $160K a year earlier — a 34.1% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $160K in the prior-year period — up 34.1% year over year. Sustained growth in intangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how PreveCeutical Medical's intangible assets evolved across reporting periods, while the comparison chart places PREV.CN next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, intangible assets is commonly used to spot outliers. PreveCeutical Medical's reading of $210K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.